The name Enurev was created for Novartis as part of their Breezhaler family of respiratory treatments.
Enurev Breezhaler contains the active substance glycopyrronium bromide and is a medicine that is used to relieve the symptoms of chronic obstructive pulmonary disease (COPD) in adults, being used for maintenance (regular) treatment.
Powerful/dynamic sounding, Enurev is derived from ‘energy’, ‘new’, ‘respire’ and ‘revolution’, it suggests trust, reliability and high-performance
Enurev fits into the Breezhaler portfolio alongside the products Seebri and Ultibro also developed by Origin.